Title: Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from
China with inflammatory bowel disease: Results from the EXPLORE study
Version: 5 Date: 18 May 2021
Reviewer's report:
This study is very interesting and well conducted. The authors investigated efficacy of anti-TNF
first line thrapy in IBD patients. As stated by the authors, the limit of the study is the fat that
infliximab was the only anti TNF approved for IBD in chinese population. However the study
is well conducted and well presented. I recommend it for publication without any revision of
the manuscript.
Title: Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from
China with inflammatory bowel disease: Results from the EXPLORE study
Version: 5 Date: 18 May 2021
Reviewer's report:
This study is very interesting and well conducted. The authors investigated efficacy of anti-TNF
first line thrapy in IBD patients. As stated by the authors, the limit of the study is the fat that
infliximab was the only anti TNF approved for IBD in chinese population. However the study
is well conducted and well presented. I recommend it for publication without any revision of
the manuscript.
Please review this paper.
user
Title: Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from
China with inflammatory bowel disease: Results from the EXPLORE study
Version: 5 Date: 18 May 2021
Reviewer's report:
This study is very interesting and well conducted. The authors investigated efficacy of anti-TNF
first line thrapy in IBD patients. As stated by the authors, the limit of the study is the fat that
infliximab was the only anti TNF approved for IBD in chinese population. However the study
is well conducted and well presented. I recommend it for publication without any revision of
the manuscript.
assistant